Kylin Therapeutics this week said it has appointed Homer Pearce to its board of directors.
Pearce was previously vice president of cancer research and clinical investigation at Eli Lilly. He holds a PhD in chemistry from Harvard University.
Homer Pearce
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.